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Abstract
Objectives: To compare the medical treatment of chronic type B aortic dissection with b-blockers versus other antihypertensive treat-
ments in terms of their requirement for surgical intervention and treatment costs. Methods: Case records of the 130 patients treated for aortic
dissection type B in this unit between 1988 and 1997 were reviewed. Seventy-eight of 130 patients with chronic dissection have received
isolated medical treatment. Seventy-one of 78 patients were discharged alive. Fifty-one of 71 received b-blocker treatment, 20/71 were
treated with other antihypertensive drugs. Results: Surgery for aortic dissection became necessary in 20/71 patients (28%) during follow-up
(mean, 4.2 years): 10/51 in the b-blocker group and 9/20 in the other antihypertensive drug group. The freedom from subsequent aortic
operation was 80 and 47%, respectively (P  0:001). Indications for emergency surgery were increased aortic diameter (79%), symptomatic
aortic aneurysm (11%), and renal artery hypoperfusion (5%). The median hospitalization time during follow-up (dissection-related) was 2
days for patients who received b-blockers and 16 days for patients who received other antihypertensive drug treatments (P  0:001). The
cost of treatment/patient per year amounted to 644 and 12 748 euros, respectively. Conclusions: A substantial proportion of patients with
chronic type B dissection who receive initial medical management will later need surgery. Long-term treatment with b-blockers reduces the
progression of aortic dilatation, the incidence of subsequent hospital admissions, as well as the incidence of late dissection-related aortic
procedures and the cost of treatment. Patients with chronic type B dissection need, in addition to frequent follow-up of aortic diameter,
continuous treatment with b-blocking agents. q 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
In contrast to Stanford classi®cation type A dissections of
the aorta, which are the most serious vascular catastrophe
[1] and which carry an extremely high early mortality due to
spontaneous rupture within the pericardium, type B dissec-
tions have a lower incidence of spontaneous rupture and
tend to become chronic [2]. Nevertheless, a substantial
proportion of patients with chronic type B dissections of
the aorta will eventually require surgery because of progres-
sive aortic dilatation. b-Blockers reduce the rate of rise (dP/
dt) of the aortic pressure wave and may prevent or retard
aortic dilatation [3±7] and reduce treatment costs.
2. Materials and methods
Between 1988 and 1997, 130 patients were treated for
aortic dissection type B at the University Hospital Zurich.
Twenty-six of 130 (20%) were female and 104/130 (80%)
were male. The mean age at the time of the hospitalization
for acute type B aortic dissection was 61 ^ 11.2 years
(range, 23±84 years). Fifty-two of 130 patients were treated
surgically, 41 as emergency and 11 urgently before
discharge. The indications for emergency surgery were:
aortic rupture (39%); ischaemia of the aortic branches
(34%); persistent pain (10%); aortic diameter of .6cm
(7%); other indications (10%). The indications for urgent
surgery (before hospital discharge) were: ischaemia of the
aortic branches (36%); left pleural effusion (18%); increas-
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ing aortic diameter (18%); persistent pain (9%); other indi-
cations (19%).
In the absence of rupture or complications of the dissec-
tions, 78/130 patients received medical treatment alone; 71/
78 of the medically treated patients were discharged alive.
Of these, 51 received treatment with b-blockers and 20 were
treated with other antihypertensive drugs. The mean age of
the medically treated patients was 64 years (61.8 ^ 8.9
years for patients who received b-blockers and
65.2 ^ 12.6 years for patients who received other antihy-
pertensive medication).
The records of all patients who were treated for type B
aortic dissection were reviewed. There were no statistically
signi®cant differences between the group given b-blockers
and the group given other antihypertensive medication with
respect to the incidence of smoking (25 and 21%, respec-
tively) and the incidence of obstructive airways disease (8.9
and 7.1%, respectively). The diameter of the aorta at the
time of diagnosis also did not differ signi®cantly between
the group given b-blockers (,4.5 cm: 41 (80%); 4.5±5.5
cm: six (12%); .5.5 cm: four (8%)) and those given other
antihypertensive medications (,4.5 cm: 15 (75%); 4.5±5.5
cm: three (15%); .5.5 cm: two (10%)). All patients who
were still alive were contacted and asked to complete a
questionnaire with the help of their doctor, in particular,
CT-scan data was collected. The total follow-up period
encompassed 194 years, with a mean observation time of
4.2 years (3.9 ^ 3.2 years for the group given b-blockers
and 4.3 ^ 2.5 years for the group given other antihyperten-
sive medications). A total of 19/130 (14.6%) patients died
during the ®rst hospitalization, and of the remaining 111
patients, follow-up was completed in 105 patients (95%);
37 patients died during follow-up.
The costs of treatment correspond to the those of the
University Hospital, Zurich. The prices cover all hospital
costs as follows: 1 day's stay in hospital, 1044 euros; 1 day's
stay in an intensive care unit, 2680 euros; major aortic
surgery, 9375 euros; 100 mg atenolol, 0.55 euros.
2.1. Statistical analysis
Variables are reported either as percentages or as
means ^ standard deviation. Statistical analyses were
performed using SPSS 6.1 software. The effects on nominal
variables were evaluated with the Chi-quadrant test and
effects on independent variables were evaluated with the
Mann±Whitney and Kruskal±Wallis tests; continuous vari-
ables were univariately evaluated with the Wilcoxon-signed
rank test. Differences between groups were analyzed using
the log-rank test. Signi®cance was assumed at a P level of
,0.05.
3. Results
Seventy-eight of 130 patients who were treated for type B
dissection, in the absence of rupture or complications of the
dissection, received medical treatment. The hospital mortal-
ity was 9% in medically treated patients compared with
9.1% for patients undergoing urgent surgery and 27% for
those with emergency surgery (Fig. 1). Seventy-one of 78 of
the medically treated patients were discharged alive. During
follow-up, 51 patients received antihypertensive treatment
with b-blockers and 20 patients received other antihyper-
tensive drugs. During follow-up, 9/51 (18%) of the b-
blocker-treated patients and 11/20 (55%) from the other
treatment group needed dissection-related surgery
(P  0:002). Increasing diameter of the aorta was the
most important indication for surgery in both groups
(Table 1). The incidence of increasing aortic diameter was
12% (6/51) in the b-blocker group and 40% (8/20) in the
other treatment group (P  0:002). The freedom from
subsequent aortic operation was 80 and 47%, respectively
(P  0:001; Fig. 2).
The median hospitalization during follow-up (related to
dissection) was 2 days for patients treated with b-blockers
and 16 days for patients treated with other antihypertensive
drugs (P  0:001). The cost of treatment/patient per year
amounted to 644 and 12 748 euros (P  0:001) for patients
given b-blockers and other antihypertensive drugs, respec-
tively.
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Fig. 1. In-hospital mortality aortic dissection type B. In-hospital mortality
(%) for aortic type B aortic dissections by time of surgical intervention
(emergency or urgent) and the treatment (medical treatment).
Table 1
Indications for late surgery indications for late surgery in chronic type B
dissection for the two therapeutic strategies: antihypertensive therapy with
and without b-blocker
b-blocker group Other antihypertensives group
Aortic diameter 6 8
Persistent pain 2 1
Lower limb ischaemia 1
Rupture 1
Visceral ischaemia 1
4. Discussion
Long-term treatment with b-blockers for chronic type B
aortic dissection reduces the progression of aortic dilatation
and the incidence of subsequent hospital admissions, as well
as the incidence of late dissection-related aortic procedures
and the cost of treatment.
It has been generally advocated that patients who have
type B acute aortic dissection without complications, such
as rupture, potential risk of rupture or organ ischaemia,
should be treated with hypotensive drugs during the acute
phase and that surgical treatment be carried out if the aortic
diameter becomes enlarged during the chronic phase [8].
The goals of early medical treatment in the acute phase
are to reduce blood pressure and heart rate, and to treat
congestive heart failure [9]. Nevertheless, 11% of all
patients treated in our institution for acute type B aortic
dissection needed surgery after the acute phase but before
discharge, most frequently because of an increase in aortic
diameter.
The pharmacological approach is aimed primarily at the
forces that in¯uence dissection propagation, namely the
pulsatile load (dP/dt) and blood pressure. Where luminal
dilatation of the aorta occurs, shear stresses on the wall
are greatly increased, according to the law of LaPlace, in
which wall tension at a constant arterial pressure, increases
with increasing luminal diameter [10]. Yin et al. have shown
that dP/dt, which is also affected by wave re¯ections (condi-
tions of increased peripheral vascular resistance), is greatest
in areas of dilatation [11]. In cases of type B dissections, the
portion of the aorta just distal to the left subclavian artery is
subject to a signi®cant degree of torsion and ¯exion during
each cardiac circle. Experimental models of aortic dissec-
tion have shown that two interrelated forces of dP/dt and
blood pressure play a part, not only in intimal tear forma-
tion, but also in the propagation of aortic dissection [1].
Studies using arti®cial aortas indicate that dissection propa-
gation occurs when the dP/dt is high and the ¯ow is pulsa-
tile, not laminar or non-turbulent. Studies in hypertensive
turkeys found that b-blockers, at doses that do not decrease
the dP/dt, afford protection from aortic dissection [12].
Additional experimental evidence from dog models
supports the role of blood pressure in the propagation of
the aortic dissection; Carney et al. showed that the depres-
sion of myocardial contractility alone does not prevent
progression of dissection, but that the inhibition of propaga-
tion can be achieved by controlled hypotension plus
myocardial depression [13].
Theoretically, the use of b-blockers offers many potential
bene®ts. The ability of b-adrenergic blockade to reduce
pulsatile force (or dP/dt) has been demonstrated in animal
models [14] and in patients with malignant hypertension
[15]. Oral b-blockade was also found to reduce the rate of
enlargement of abdominal aortic aneurysms in humans [16].
Furthermore, b-blockers decrease the sympathetic tone and
increase the parasympathetic tone, thus improving auto-
nomic imbalance. In our series, the positive in¯uence of
b-blocker therapy is re¯ected in a signi®cantly lower
increase of aortic diameter and a signi®cantly lower inci-
dence of dissection-related surgical intervention in chronic
type B aortic dissection. Therefore, the presumptive bene®ts
of b-blockers derive not only from their impact on blood
pressure, but also from their negative inotropic and chron-
otropic properties. This is why some authorities do not
recommend vasodilators without concomitant administra-
tion of a drug with negative inotropic and chronotropic
effects. However, such an approach may actually increase
the velocity of left ventricular contraction (dP/dt) and make
the dissection worse. For the same reason, sublingual use of
nifedipine is controversial; it reduces blood pressure in an
uncontrolled fashion, potentially causing a re¯ex increase in
heart rate and contractility, and thus, increasing the dP/dt
[9].
Since serious early complications of type B dissection are
not uncommon and unexpected late rupture (which is almost
invariably fatal) cannot reliably be predicted, there has been
an increasing tendency to operate on acute and subacute
type B dissections [17]. The indication for emergency
surgery after the acute phase of a type B aortic dissection
must be balanced against the not inconsiderable morbidity
and mortality rates carried by emergency surgery (Fig. 1).
Although surgery is steadily improving, the risk is still quite
substantial and there are few guidelines to suggest patients
could justi®ably be exposed to these surgical risks, apart
from those with very large aneurysms or pronounced symp-
toms. Furthermore, it is known that age and chronic obstruc-
tive pulmonary disease are powerful predictors of rupture of
chronic type B dissection [18,19]. It has been speculated
that there must be a common, possibly smoking-related
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Fig. 2. Freedom from any event ± chronic aortic dissection type B. Freedom
from any event in patients with chronic type B aortic dissection, beginning
from the discharge of the ®rst hospitalization.
defect in connective tissue metabolism that predisposes
towards both lung and aortic pathology in susceptible
persons. On the other hand, our series shows a good survival
rate and a good rate of freedom from any event. The low
hospitalization rate of patients treated strictly with b-block-
ers and the low treatment cost/patient per year are further
reasons to encourage a positive view of a medical approach
to type B aortic dissection which includes frequent treat-
ment review, as well as regular determination of aortic
diameter.
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Appendix A. Conference discussion
Dr C. Alhan (Istanbul, Turkey): Was there a contraindication for b-
blocker usage in patients not using b-blockers? That's my ®rst question.
Dr Genoni: We had only one patient with severe peripheral arterial
disease who had contraindications to b-blockers. All other patients did
not show signs of contraindication. And it's important to say that this is a
retrospective study, so we had no chance to change their medical treatment
in the follow-up time.
Dr Alhan: My second question is, did you look at the initial aortic diameter
at the time of dissection? Was there a difference between the two groups?
Dr Genoni: No. The diameter is comparable for the two groups. The
univariate analysis of our patients revealed that a diameter larger than 4.5
cm is a predictor for surgery in the follow-up and also for death. Based on
these observations, the indications for surgery is a diameter of 4.5 cm.
Dr R. Ascione (Bristol, UK): I have a few questions to ask. First, did you
actually control the blood pressure during your follow-up period?
Dr Genoni: Yes. The values of blood pressure are comparable for both
groups.
Dr Ascione: Was the blood pressure controlled? I mean was it in the right
range?
Dr Genoni: Yes, retrospectively with the questionnaire we sent to the
patients.
Dr Ascione: If that's the case, I would like to ask you which is the
underlying mechanism allowing the b-blockers to achieve this advantage?
Dr Genoni: Theoretically, the use of b-blockers offers many potential
bene®ts: ®rstly a decrease of the blood pressure; then reduction of the
pulsatile force (dP/dt); and ®nally, decreasing of the sympathetic tone.
Around that, I think that the bene®t of b-blockers derives not only from
the direct impact of the blood pressure, but also from the negative inotropic
and chronotropic properties.
Dr Ascione: So, we should then conclude that the most important thing is
not controlling blood pressure. I mean this is the message we are getting.
Dr Genoni: I think both are very important. So, if you cannot control the
blood pressure with b-blockers only, you need additional medication.
Dr A. Arbulu (Detroit, MI, USA): Your work con®rms the suggestion of
Dr Myron Wheat over 30 years ago.
Our experience is very similar to yours, and although those patients had
antihypertensive therapy, you show that some of those came to surgery. In a
very small series, we found that the control of the hypertension at home was
not the same as it used to be while they were in the hospital. We were able
to obtain this information from a group of visiting nurses. I wonder if you
had, in your experience, any out-of-hospital follow-up?
Dr R. Griepp (New York, NY, USA): To the best of my knowledge, this
is the ®rst published account that b-blockers actually have a bene®cial
effect on the natural history of aortic disease in patients other than those
with Marfan's syndrome. My ®rst question is, whether you are aware of
any other published accounts that show a bene®cial effect of b-blockers
per se?
My second question relates to your graph of freedom from adverse events
after acute dissection; it appears that most of the bene®t of the b-blockers
occurs in the ®rst year and that thereafter, the lines are parallel. Do you think
that this phenomenon is real, does it mean we only need to use b-blockers in
the ®rst year or is this apparent concentration of the bene®ts in the ®rst year an
artefact of the study for which you have another explanation?
Dr Genoni: I don't know. Our results call for a very strict follow-up
examination of the diameter of the aorta. Furthermore, it is mandatory for
all patients to take b-blockers for the rest of their lives.
Dr M. Turina (Zurich, Switzerland): If I may add, that's the second conse-
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quence of this paper. Probably the equally important one is the need for very
strict follow-up in the ®rst 2±4 years. Our incidence of adverse events, after 4
years, becomes ¯at, but in the ®rst 4 years, this patient needs very careful
follow-up, otherwise you will have a substantial mortality in this period, and
this is the second message which Dr Genoni is bringing to you.
Dr R. Martinez (Tenerife, Spain): Do you use b-blockers in chronic
bronchial disease?
Dr Genoni: If the patient tolerates the medication, we'll prescribe it. It
depends on the patient.
Dr Turina: The question really is, do we know how many patients were
put on b-blockers and had to be taken off? Do you have this data?
Dr Genoni: We had only one patient with a contraindication to b-block-
ers.
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